Abstract
Tebentafusp, a Tcell-redirecting, bispecific-antibody-targeting, HLA∗02:01-restricted gp100 peptide and CD3, induces Tcells to kill glycoprotein 100 (gp100)-expressing tumor cells. Tebentafusp is the first Tcell engager to show a statistically significant overall survival improvement for the treatment of patients with solid tumors, and this has been reported in the New England Journal of Medicine.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call